PE20010628A1 - Compuestos de amina ciclica, su produccion y su uso - Google Patents
Compuestos de amina ciclica, su produccion y su usoInfo
- Publication number
- PE20010628A1 PE20010628A1 PE2000001025A PE0010252000A PE20010628A1 PE 20010628 A1 PE20010628 A1 PE 20010628A1 PE 2000001025 A PE2000001025 A PE 2000001025A PE 0010252000 A PE0010252000 A PE 0010252000A PE 20010628 A1 PE20010628 A1 PE 20010628A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrocarbon
- divudina
- heterocycle
- link
- methylsulfonil
- Prior art date
Links
- -1 AMINE COMPOUNDS Chemical class 0.000 title abstract 6
- 239000004215 Carbon black (E152) Substances 0.000 abstract 5
- 229930195733 hydrocarbon Natural products 0.000 abstract 5
- 150000002430 hydrocarbons Chemical class 0.000 abstract 5
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 102000009410 Chemokine receptor Human genes 0.000 abstract 1
- 108050000299 Chemokine receptor Proteins 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 229960001830 amprenavir Drugs 0.000 abstract 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960001936 indinavir Drugs 0.000 abstract 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 1
- 229960001852 saquinavir Drugs 0.000 abstract 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 abstract 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE REFIERE A UNA AMINA CICLICA DE FORMULA I; R1 ES H, HIDROCARBURO SUSTITUIDO POR UN HETEROCICLO; R2 ES UN HIDROCARBURO SUSTITUIDO POR UN HETEROCICLO O R1 Y R2 JUNTO CON A FORMAN UN HETEROCICLO; A ES N, N(+)(-R5).Y(-); R5 ES UN HIDROCARBURO; Y ES UN CONTRAANION; R3 ES UN HIDROCARBURO CICLICO, HETEROCICLO; n ES 0-1; R4 ES H, HIDROCARBURO, HETEROCICLO, ALCOXI, ARILOXI, AMINO; E ES UN HIDROCARBURO ALIFATICO DIVALENTE; G1 ES UN ENLACE, CO, SO2; G2 ES CO, SO2, NHCO, CONH, OCO; J ES METINA, N; Q Y R SON UN ENLACE, HIDROCARBURO ALIFATICO C1-C3; J ES METINA, CUANDO G2 ES OCO; UNO DE Q Y R ES UN ENLACE. SON COMPUESTOS PREFERIDOS N-(3,4-DICLOROFENIL)-1-(METILSULFONIL)-N-{3-[4-({4-[(METILSULFONIL)AMINO]FENIL}SULFONIL)-1-PIPERINIL]PROPIL}-4-PIPERIDINCARBOXAMIDA; N-(3-CLOROFENIL)-1-(METILSULFONIL)-N-(3-{4-[4-(METILSULFONIL)BENCIL]-1-PIPERIDINIL}PROPIL)-4-PIPERINCARBOXAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UN INHIBIDOR DE PROTEASA COMO SAQUINAVIR, RITONAVIR, INDINAVIR, AMPRENAVIR, ENTRE OTROS, UN INHIBIDOR DE TRANSCRIPTASA INVERSA COMO ZIDOVUDINA, DIDANOSINA, ZALCITABINA, LAMIVUDINA, ABACAVIR, ENTRE OTROS Y A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR DE QUIMIOCINA, CCR5 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD INFECCIOSA POR VIH
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28208899 | 1999-10-01 | ||
| JP2000046749 | 2000-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010628A1 true PE20010628A1 (es) | 2001-06-18 |
Family
ID=26554466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001025A PE20010628A1 (es) | 1999-10-01 | 2000-09-28 | Compuestos de amina ciclica, su produccion y su uso |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6562978B1 (es) |
| EP (2) | EP1220842B1 (es) |
| JP (2) | JP3814136B2 (es) |
| KR (1) | KR20020060190A (es) |
| CN (1) | CN1390201A (es) |
| AR (1) | AR025884A1 (es) |
| AT (1) | ATE400555T1 (es) |
| AU (1) | AU7448700A (es) |
| BR (1) | BRPI0014428B8 (es) |
| CA (2) | CA2385938C (es) |
| CO (1) | CO5380013A1 (es) |
| CY (1) | CY1108403T1 (es) |
| DE (1) | DE60039446D1 (es) |
| DK (1) | DK1220842T3 (es) |
| ES (1) | ES2310173T3 (es) |
| HU (1) | HUP0300138A3 (es) |
| NO (1) | NO20021450L (es) |
| PE (1) | PE20010628A1 (es) |
| PL (1) | PL203984B1 (es) |
| PT (1) | PT1220842E (es) |
| WO (1) | WO2001025200A1 (es) |
| ZA (1) | ZA200202593B (es) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| AU2001288110A1 (en) * | 2000-09-27 | 2002-04-08 | Takeda Chemical Industries Ltd. | Spiro compounds |
| SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| EP1354587A1 (en) * | 2000-12-22 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Medicinal compositions for oral use |
| CN1494529A (zh) * | 2001-01-18 | 2004-05-05 | 武田药品工业株式会社 | 苄基哌啶化合物的制备方法 |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| WO2002088089A1 (en) * | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions |
| WO2003089004A1 (fr) * | 2002-04-19 | 2003-10-30 | Takeda Pharmaceutical Company Limited | Agents prophylactiques utilises pour prevenir l'infection par vih |
| US20050245537A1 (en) * | 2002-04-24 | 2005-11-03 | Noboru Tsuchimori | Use of compounds having ccr antagonism |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| WO2004026833A1 (ja) * | 2002-09-20 | 2004-04-01 | Takeda Pharmaceutical Company Limited | 環状アミン化合物、その製造法および用途 |
| WO2004035581A1 (ja) * | 2002-10-18 | 2004-04-29 | Ono Pharmaceutical Co., Ltd. | スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤 |
| AU2003290323A1 (en) * | 2002-12-24 | 2004-07-22 | Biofocus Plc | Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| US7491735B2 (en) | 2003-12-11 | 2009-02-17 | Genzyme Corporation | Chemokine receptor binding compounds |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| SE0403084D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Chemical process |
| BRPI0516407A (pt) * | 2004-12-24 | 2008-09-02 | Prosidion Ltd | agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes |
| BRPI0519288A2 (pt) | 2004-12-24 | 2009-01-06 | Astrazeneca Ab | compostos heterocÍclicos como antagonistas de ccr2b |
| WO2006130426A2 (en) * | 2005-05-27 | 2006-12-07 | Kemia, Inc. | Modulators of ccr-5 activity |
| AU2013200480B2 (en) * | 2006-02-28 | 2016-06-09 | Dart Neuroscience (Cayman) Ltd. | Therapeutic compounds |
| SG171635A1 (en) | 2006-02-28 | 2011-06-29 | Helicon Therapeutics Inc | Therapeutic piperazines as pde4 inhibitors |
| EP1989185B8 (en) * | 2006-02-28 | 2013-06-26 | Dart NeuroScience LLC | Therapeutic compounds |
| WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| US8791264B2 (en) * | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| WO2008073450A2 (en) * | 2006-12-12 | 2008-06-19 | Georgetown University | Benzamide compounds |
| GB0625523D0 (en) * | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
| US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| WO2009029632A1 (en) | 2007-08-27 | 2009-03-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| AU2008307572A1 (en) | 2007-10-04 | 2009-04-09 | Merck Sharp & Dohme Corp. | Substituted aryl sulfone derivatives as calcium channel blockers |
| WO2011102436A1 (ja) * | 2010-02-17 | 2011-08-25 | 国立大学法人京都大学 | ＴＧＦ－βシグナル伝達阻害剤 |
| AR080374A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida |
| EA201290852A1 (ru) | 2010-04-02 | 2013-04-30 | ФИВКО-1 ЭлЭлСи | Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель |
| CN101921224B (zh) * | 2010-05-21 | 2012-01-18 | 中国人民解放军军事医学科学院生物工程研究所 | 1-（3-氨基丙基）哌嗪-4-氨基酰胺类化合物及其制备方法与应用 |
| KR200453948Y1 (ko) * | 2011-02-28 | 2011-06-09 | 최문희 | 파마로드 |
| WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| CN103130709B (zh) * | 2011-11-22 | 2017-04-12 | 常州亚邦制药有限公司 | 具有抗hiv活性的3‑氨基丙酸哌啶酰胺类化合物，合成方法及用途 |
| JP5977837B2 (ja) | 2011-12-21 | 2016-08-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| NZ743463A (en) | 2012-08-28 | 2019-09-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| MX366123B (es) | 2013-02-28 | 2019-06-27 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b. |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| CN105960400B (zh) | 2013-05-17 | 2019-05-31 | 爱尔兰詹森科学公司 | 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| PL3024819T3 (pl) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
| EP3060547B1 (en) * | 2013-10-23 | 2017-10-11 | Janssen Sciences Ireland UC | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US20150216938A1 (en) | 2014-02-05 | 2015-08-06 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
| CN110483484A (zh) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| EP3233799B1 (en) | 2014-12-19 | 2021-05-19 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| US10633336B2 (en) | 2014-12-19 | 2020-04-28 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| CN109640980A (zh) | 2016-04-15 | 2019-04-16 | 诺维拉治疗公司 | 包含壳体装配抑制剂的组合和方法 |
| ES2919779T3 (es) | 2017-06-20 | 2022-07-28 | Imbria Pharmaceuticals Inc | Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco |
| CA3090125A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| WO2020028482A1 (en) * | 2018-07-31 | 2020-02-06 | The Trustees Of The University Of Pennsylvania | Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity |
| EP4497474A3 (en) | 2018-10-17 | 2025-04-23 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| JP2022521081A (ja) | 2019-02-22 | 2022-04-05 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体 |
| MA55879A (fr) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| CN114478585A (zh) * | 2020-10-26 | 2022-05-13 | 上海青煜医药科技有限公司 | 含氮稠杂环类化合物及其制备方法和应用 |
| CN117098560A (zh) * | 2021-04-23 | 2023-11-21 | 中国人民解放军军事科学院军事医学研究院 | 抗病毒多肽化合物 |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| WO2023107547A2 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Azetidine and spiroazetidine compounds and uses thereof |
| CA3257803A1 (en) | 2022-06-13 | 2025-04-04 | Alivexis, Inc. | AZACYCLOLAKYL CARBONYL CYCLIC AMINE COMPOUND |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203988A (en) | 1975-11-12 | 1980-05-20 | Merck & Co., Inc. | Pyridinyl ureas and pharmaceutical use |
| JPH0680054B2 (ja) * | 1985-06-19 | 1994-10-12 | 吉富製薬株式会社 | ピペリジン誘導体 |
| EP0693070B1 (en) * | 1993-04-05 | 2002-07-24 | Pharmaceutical Discovery Corporation | PYRIDO[2,3-b](1,4)BENZODIAZEPINONES AS M2 RECEPTOR LIGAND FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| EP1003514A4 (en) | 1997-07-25 | 2000-10-11 | Merck & Co Inc | CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| CA2319781A1 (en) | 1998-02-02 | 1999-08-05 | Liping Wang | Cyclic amine modulators of chemokine receptor activity |
| CN1494529A (zh) * | 2001-01-18 | 2004-05-05 | 武田药品工业株式会社 | 苄基哌啶化合物的制备方法 |
-
2000
- 2000-09-28 AR ARP000105104A patent/AR025884A1/es not_active Application Discontinuation
- 2000-09-28 PE PE2000001025A patent/PE20010628A1/es not_active Application Discontinuation
- 2000-09-29 PL PL356034A patent/PL203984B1/pl unknown
- 2000-09-29 CA CA2385938A patent/CA2385938C/en not_active Expired - Lifetime
- 2000-09-29 DE DE60039446T patent/DE60039446D1/de not_active Expired - Lifetime
- 2000-09-29 CN CN00815683A patent/CN1390201A/zh active Pending
- 2000-09-29 KR KR1020027004238A patent/KR20020060190A/ko not_active Abandoned
- 2000-09-29 CA CA002608807A patent/CA2608807A1/en not_active Abandoned
- 2000-09-29 EP EP00962967A patent/EP1220842B1/en not_active Expired - Lifetime
- 2000-09-29 DK DK00962967T patent/DK1220842T3/da active
- 2000-09-29 BR BRPI0014428A patent/BRPI0014428B8/pt not_active IP Right Cessation
- 2000-09-29 AT AT00962967T patent/ATE400555T1/de active
- 2000-09-29 EP EP07119933A patent/EP1886994A1/en not_active Withdrawn
- 2000-09-29 US US10/089,374 patent/US6562978B1/en not_active Expired - Lifetime
- 2000-09-29 WO PCT/JP2000/006755 patent/WO2001025200A1/en not_active Ceased
- 2000-09-29 CO CO00074305A patent/CO5380013A1/es not_active Application Discontinuation
- 2000-09-29 AU AU74487/00A patent/AU7448700A/en not_active Abandoned
- 2000-09-29 PT PT00962967T patent/PT1220842E/pt unknown
- 2000-09-29 ES ES00962967T patent/ES2310173T3/es not_active Expired - Lifetime
- 2000-09-29 HU HU0300138A patent/HUP0300138A3/hu unknown
- 2000-09-29 JP JP2000302841A patent/JP3814136B2/ja not_active Expired - Lifetime
-
2002
- 2002-03-22 NO NO20021450A patent/NO20021450L/no not_active Application Discontinuation
- 2002-04-03 ZA ZA200202593A patent/ZA200202593B/en unknown
- 2002-06-20 JP JP2002180545A patent/JP2003048880A/ja not_active Withdrawn
- 2002-10-18 US US10/273,111 patent/US7348324B2/en not_active Expired - Lifetime
-
2008
- 2008-10-08 CY CY20081101116T patent/CY1108403T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010628A1 (es) | Compuestos de amina ciclica, su produccion y su uso | |
| PE20040780A1 (es) | Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion | |
| ES2572980T3 (es) | Combinación de inhibidores de la proteasa del VHC con un tensioactivo | |
| PE20010987A1 (es) | Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
| PE20091567A1 (es) | Derivados de metastina en el tratamiento del cancer | |
| PE20040892A1 (es) | Antagonistas del receptor muscarinico m3 de acetilcolina | |
| PE20040120A1 (es) | Derivados de quinolina como antagonistas de npy | |
| DE3850203D1 (de) | Benzimidazolin-2-oxo-1-carboxylsäure-Derivate, verwendbar als Antagonisten von 5-HT-Rezeptoren. | |
| PE20050018A1 (es) | Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b) | |
| AR035320A1 (es) | Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta | |
| PE20060076A1 (es) | Antagonistas del receptor de acetilcolina muscarinico | |
| PE20040241A1 (es) | Inhibidores proteasa hiv, composiciones que los contienen y materiales para sus sintesis | |
| CR8595A (es) | Inhibidor del dipeptidil-peptidasa | |
| BR0312811A (pt) | Monoetano sulfonato de 3-z-[1-(4-(n-((4-metil piperazin-1-il) metil carbonil)-n-metil-amino) anilino)-1-fenil-metileno]-6-metóxi carbonil-2-indolinona e seu uso com uma composição farmacêutica | |
| PE20090434A1 (es) | Derivados de sulfonil amida como inhibidores de quinasas | |
| PE20001562A1 (es) | Derivados de benzamida como inhibidores de la produccion hepatica de la apo proteina b-100 | |
| CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| PE20001387A1 (es) | Compuestos empleados en el tratamiento de padecimientos inflamatorios | |
| PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| AR051965A1 (es) | Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida | |
| PE20090595A1 (es) | Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1 | |
| AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
| PE20051036A1 (es) | Antagonistas del receptor peptido relacionado con el gen de calcitonina | |
| PE20061013A1 (es) | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |